News

Jerusalem, Israel, January 2, 2002 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U. S. Food and Drug Administration (FDA) has issued tentative approval for Ciprofloxacin tablets 250, 500 and 750 mg.Ciprofloxacin is the generic version of Bayer's Cipro® for the treatment of bacterial infections. Cipro® has annual U.S. sales of approximately $ 950 million. Final approval is not anticipated until the resolution of issues associated with the December 2003 patent. It is expected that there will be multiple competitors.Teva had already received tentative approval for Read More »

Jerusalem, Israel, January 16, 2002 - Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) announced today that the U.S. Food and Drug Administration (FDA) has awarded tentative approval for Mirtazapine tablets, 15 mg, 30 mg and 45 mg.Mirtazapine tablets are the AB-rated generic version of Organon's branded product Remeron®. The tentative approval is for the use of Mirtazapine as monotherapy for the treatment of depression.Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 40 pharmaceutical companies and among the largest generic pharmaceutical companies in the world. Read More »

Jerusalem, Israel, January 17, 2002 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U. S. Food and Drug Administration has granted "approvable" status for Tramadol Hydrochloride Tablets, 50 mg.Tramadol Hydrochloride Tablets are the AB-rated generic version of RW Johnson's Ultram for the management of pain. Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 40 pharmaceutical companies and among the largest generic pharmaceutical companies in the world. Over 80% of Teva's sales are in North America and Europe. The company develo Read More »

Jerusalem, Israel, January 25, 2002 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U. S. Food and Drug Administration (FDA) has granted final approval for Metformin Tablets, 500 and 850 mg. Teva USA will launch the product immediately.Metformin Tablets are the generic equivalent of Bristol-Myers Squibb's antihyperglycemic drug, Glucophage, which is indicated as an adjunct to diet to lower blood glucose levels in patients with type 2 diabetes. 2001 U.S. branded sales for these two dosages were approximately $1.1 billion. Teva Pharmaceutical Industries Ltd., headqu Read More »

Jerusalem, Israel, January 29, 2002 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has granted final approval for Fluoxetine 10, 20 and 40 mg capsules and for Fluoxetine 10 mg tablets. Teva now has approval for all Fluoxetine dosages, and will launch these new forms immediately.Fluoxetine is the generic version of Eli Lilly's antidepressant drug - Prozac®.2001 brand sales of Fluoxetine capsules in the USA were approximately $ 2.1 billion and Fluoxetine 10mg tablets were approximately $ 80 million. Teva Pharmaceutical Indust Read More »

Jerusalem, Israel, February 5, 2002 - Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) today announced that it has made a firm offer to acquire Bayer Pharma S.A.'s French generic business including marketing and manufacturing activities. The offer includes Bayer Classics S.A. a leading supplier of generic pharmaceutical products to the French retail market. Notification of Teva's offer has been made to the workers' committees of Bayer in accordance with French law. The potential acquisition in the emerging French generic market is in line with Teva's strategy to be a global generic leader and Read More »

Jerusalem, Israel, February 5, 2002 - Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) today announced that Copaxone® will be available in the U.K. under the new National Health Service (NHS) scheme.The U.K. department of health announced yesterday that a special risk- sharing scheme will be implemented from May this year. The scheme will ensure that patients who meet criteria devised by the Association of British Neurologists can be prescribed MS pharmaceuticals. The number of U.K. MS patients is the second largest in Europe.Glyn Wright, General Manager of Teva U.K. said: " This new sch Read More »

Jerusalem, Israel, February 6, 2002 - Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) today announced it will release its fourth quarter and full year 2001 financial results on Thursday, February 14, 2002. The company will host a conference call on that date at 10:00 a.m. (Eastern Standard Time) to review its financial results.The conference call will be broadcast simultaneously over the Internet and can be accessed by visiting the Company's Web site at www.tevapharm.com. Please log on to the Web site at least 15 minutes prior to the scheduled call time to download and install any necessary Read More »

Jerusalem, Israel, February 11, 2002 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has granted tentative approval for Quinapril HCL 5, 10, 20 and 40 mg tablets. This is the first tentative approval granted by FDA for Quinapril.Quinapril is the generic version of Parke Davis' Accupril® for the treatment of hypertension, and Teva is currently involved in paragraph IV litigation with Pfizer/Parke Davis concerning this product.Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 40 pharmaceutical comp Read More »

Highlights - Fourth Quarter Revenues Increased 9% to $567 Million and Full-Year Revenues Grew 19% to $2.08 BillionFourth Quarter Net Income Increased 54% to $89 Million or $0.66* per Fully Diluted Share and Full Year Net Income Grew 56% to $288* Million or 50% to $2.11* per Fully Diluted ShareFourth Quarter In-Market Sales of Copaxone® Increased 42% to $102 Million and Full-Year Sales Grew 47% to $363 Million* Before one-time charges Jerusalem, Israel, February 14, 2002 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today reported net income, excluding one-time charges, for the fourth q Read More »